Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results ...

Kymera (KYMR) Q3 2026 Earnings Call Transcript

KT-579 IRF5 degrader hit 94% degradation in Phase I trials.

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

NEW YORK — Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a webcast at 4:30 p.m. EST on Monday, November 9, 2026 to report financial results for the third quarter ended […]

Kymera Therapeutics Q3 Earnings Call Highlights

Kymera Therapeutics (NASDAQ:KYMR) reported third-quarter results and outlined progress across its clinical pipeline, including phase I healthy-volunteer data for KT-579, an oral degrader targeting IRF5 for autoimmune diseases. The company also said it expects to report phase IIb data for its STAT6 d

Kymera Therapeutics GAAP EPS of -$1.32 misses by $0.05

Kymera Therapeutics press release (KYMR): Q3 GAAP EPS of -$1.32 misses by $0.05.

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results ...

KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results - PressReach

– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in … Continue reading "PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial R…